Xinhua Pharmaceuticals: OAB-14 dry suspension completed phase II clinical trial with the first patient in China recruited.

Xinhua Pharmaceutical announced that the Phase II clinical trial of OAB-14 dry suspension for the treatment of mild to moderate Alzheimer's disease has successfully enrolled the first patient in China. The Phase II clinical trial of OAB-14 dry suspension is jointly conducted by Xinhua Pharmaceutical and the Xuanwu Hospital of Capital Medical University, with multiple national centers participating. The first patient in China was enrolled on June 19, 2025. OAB-14 is a new chemical structure innovative drug with independent intellectual property rights developed by Xinhua Pharmaceutical in collaboration with Shenyang Pharmaceutical University, and belongs to the category of Class 1 innovative drugs.